The Effects of Intravesical Therapy with Hyaluronic Acid for Painful Bladder Syndrome: Preliminary Chinese Experience and Systematic Review

Overview

Journal Taiwan J Obstet Gynecol

Publisher Elsevier

Specialty Gynecology & Obstetrics

Date 2015 Jul 14

PMID 26166334

Citations 5

Authors

Xiao-Min Han

Xin-Hua Wu

Bing Li

Feng Pan

Wen-Cheng Li

Shu-Lan Liu

Fu-Qing Zeng

Min Chen

Affiliations

Soon will be listed here.

Abstract

Objective: To present the preliminary results of treating a series of Chinese patients with painful bladder syndrome/interstitial cystitis (PBS/IC) using intravesical hyaluronic acid (HA).

Materials And Methods: A series of 13 patients with PBS/IC received first-line therapy followed by HA once-a-week for 4 weeks and then once monthly for 4 months. Outcomes measured included O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and Interstitial Cystitis Problem Index (ISPI) scores, voiding frequency, and bladder capacity.

Results: ISPI and ICSI scores were significantly (p < 0.001) decreased after treatment [median change (interquartile range): ISPI = 2 (2-3); ICSI = 3 (2-3)]. Voiding frequency and functional bladder capacity were significantly (p < 0.001) decreased [median change: 7 (6-8) times/d] and increased [median change: 190 (116-233) mL], respectively after treatment.

Conclusion: Our case series supports the efficacy of intravesical HA in the treatment of PBS/IC.

Citing Articles

Glycosaminoglycan Replacement Therapy with Intravesical Instillations of Combined Hyaluronic Acid and Chondroitin Sulfate in Patients with Recurrent Cystitis, Post-radiation Cystitis and Bladder Pain Syndrome: A Narrative Review.

Poletajew S, Brzozka M, Krajewski W, Kamecki H, Nyk L, Kryst P Pain Ther. 2023; 13(1):1-22.

PMID: 37917298 PMC: 10796878. DOI: 10.1007/s40122-023-00559-1.

Potassium sensitivity test predicts hydrodistention efficacy in patients with bladder pain syndrome/interstitial cystitis.

Gulpinar O, Esen B, Akpinar C, Baklaci U, Gokce M, Suer E Turk J Urol. 2019; 46(3):231-235.

PMID: 31747364 PMC: 7219972. DOI: 10.5152/tud.2019.19084.

Role of NLRP3 inflammasome in the development of bladder pain syndrome interstitial cystitis.

Tudrej K, Piecha T, Kozlowska-Wojciechowska M Ther Adv Urol. 2019; 11:1756287218818030.

PMID: 30671141 PMC: 6329030. DOI: 10.1177/1756287218818030.

Gold nanoparticles approach to detect chondroitin sulphate and hyaluronic acid urothelial coating.

Guelfi G, Stefanetti V, Zampini D, Oommen O, Brecchia G, DallAglio C Sci Rep. 2017; 7(1):10355.

PMID: 28871206 PMC: 5583281. DOI: 10.1038/s41598-017-09872-0.

Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence.

Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G Ther Adv Urol. 2016; 8(2):91-9.

PMID: 27034722 PMC: 4772357. DOI: 10.1177/1756287215621234.